Has Todd Berinstein, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,726 in general payments to Todd Berinstein, MD across 197 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Todd Berinstein, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Todd Berinstein, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Todd Berinstein, MD

Otolaryngology · Vancouver, WANPI 1508826744

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Optinose US, Inc. at 33.6% of the total. Reporting peaked in 2019 at $5,336 and has fallen 93.6% since, to $344 in 2024. Among otolaryngology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,726in general payments, 2019–2025

Across 197 payments — averaging $69.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Optinose US, Inc.$5K
Aerin Medical Inc.$2K
Medical Device Business Services, Inc.$2K
GSK$1K
Intersect ENT, Inc.$802
Acclarent, Inc$665
plus $2K from 14 others

What the payments were for

Consulting fees$3,13023%
Travel & lodging$3,71927%
Food & beverage$6,87750%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Optinose US, Inc.	32	$4,618
Aerin Medical Inc.	24	$2,128
Medical Device Business Services, Inc.	3	$1,950
GSK	46	$1,357
Intersect ENT, Inc.	21	$802
Acclarent, Inc	13	$665
Medtronic(2 entities)	10	$573
Regeneron Healthcare Solutions, Inc.	10	$371
Sanofi	10	$305
Alk-abello, Inc	6	$241
Pharming Healthcare, Inc.	2	$148
Kaleo, Inc.	6	$148
Med-el Corporation	4	$144
Stryker	2	$83
AbbVie	1	$70
Novartis	2	$33
Smith+Nephew	2	$32
Merck	1	$26
Livanova USA, Inc.	1	$16
Biohaven Pharmaceutical Holding Company Ltd.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Xhance$3,981
VIVAER STYLUS$1,078
NUCALA$484
PROPEL$389
NUVENT$323
DUPIXENT$248
TruDi Nav Cable$244
Vivaer RF Stylus$143
Odactra$139
RHINAER STYLUS$127
JOENJA$125
Acclarent Navwire$125
TRELEGY ELLIPTA$117
RELIEVA SPINPLUS Balloon Sinuplasty System$114

How this compares

$13,726 in reported general payments places this provider in the 95th percentile of 254 otolaryngology providers in Washington.

See all otolaryngology providers in Washington →

Medicare billing

Part B allowed, 2024

$63,671

Medicare patients

262

Services billed

1,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	13	$47,795
Dupixent SyringeDupilumab	13	$46,426
Ipratropium Bromide	78	$3,327
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth	13	$1,341
Omeprazole	57	$1,046
Fluticasone Propionate	41	$616
Clindamycin Hcl	15	$102
Azithromycin	14	$76
Pantoprazole Sodium	12	$33

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Vancouver

Jonathan ZwartVancouver$3K
David BloomVancouver$2K
Greg DavisPuyallup$531K
Ian HumphreysSeattle$43K
Douglas BackousPuyallup$36K
Craig MillerSeattle$24K
Sachin GuptaSeattle$23K
Sharon CushingSeattle$19K
Ronald KruegerMukilteo$19K
Eric WatermanBellevue$15K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →